From: Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
 | r/n | OR (unadjusted), 95% CI | p | aOR (adjusted), 95% CI | p |
---|---|---|---|---|---|
Treatment | |||||
 HRZE | 30/326 (33) |  |  | 1.0 |  |
 2MHRZ/2MHR | 55/312 (32) | 2.22 (1.36–3.62) | 0.001 | 2.24 (1.37–3.65) | 0.001 |
 2EMRZ/2MR | 78/336 (35) | 3.31 (2.07–5.29) | < 0.001 | 3.31 (2.07–5.28) | < 0.001 |
Age | |||||
 ≤ 30 years | 58/435 | 1.0 |  | 1.0 |  |
 > 30 years | 105/539 | 1.46 (1.00–2.12) | 0.045 | 1.48 (1.02–2.14) | 0.037 |
BMI | |||||
 < 18.5 | 105/547 | 1.0 |  | 1.0 |  |
 ≥ 18.5 | 58/427 | 0.65 (0.45–0.93) | 0.020 | 0.64 (0.44–0.92) | 0.017 |
Race | |||||
 Asian | 50/311 | 1.0 |  |  |  |
 Black | 70/430 | 0.85 (0.55–1.32) | 0.469 | – | – |
 Mixed race and Caucasian | 43/233 | 0.97 (0.58–1.61) | 0.902 |  |  |
Smoking | |||||
 Never smoked | 39/334 | 1.0 |  | 1.0 |  |
 Ever smoked | 124/640 | 1.61 (1.04–2.49) | 0.034 | 1.60 (1.07–2.40) | 0.023 |
HIV | |||||
 Negative | 143/922 (95) | 1.0 |  | 1.0 |  |
 Positive | 20/52 | 4.26 (2.22–8.18) | < 0.001 | 3.97 (2.12–7.42) | < 0.001 |
Cavities | |||||
 No cavities | 16/198 | 1.0 |  | 1.0 |  |
 Cavities | 147/776 | 2.78 (1.59–4.85) | < 0.001 | 2.78 (1.59–4.84) | < 0.001 |